[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Luzerner Kantonsspital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":409},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,46,73,111,140,183,209,239,255,275,298,324,347,371,390],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639671","cerebellum-and-neglect-100639671",false,"NCT07580066","Cerebellum and Neglect","The Role of the Cerebellum in Recovery of Visual Neglect","Inclusion Criteria:\n\n* First-ever, subacute right hemispheric stroke\n* Left-sided visual neglect defined by MGP \\> 1.333°\n* Age ≥18 years\n* Normal or corrected-to-normal visual acuity\n* MRI compatibility (MRI-based neuronavigation for cTBS)\n* Capacity to consent and ability to follow study procedures\n\nExclusion Criteria:\n\n* Cerebellar lesion\n* History of epilepsy\n* Metallic implants in the head region\n* Scalp or skin conditions that interfere with EEG electrode placement (e.g. open wounds, infections, severe psoriasis)\n* Co-morbidities including: neurological, degenerative or major psychiatric disorder (other than index stroke), alcohol or drug abuse, severe liver or kidney disease, and active malignant tumor disease\n* Pregnancy\n* Enrolment in an ongoing clinical trial","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if a non-invasive brain stimulation method called continuous theta burst stimulation (cTBS) can improve attention in adults who have hemispatial neglect after stroke. Hemispatial neglect is a common consequence of stroke where a person fails to notice things on one side of their environment and body after brain damage despite having intact sensory organs. Current treatments include physiotherapy, occupational therapy, and visual scanning training.\n\nThe main questions it aims to answer are:\n\n* Does cTBS applied to the cerebellum shift spatial attention toward the neglected side, as measured by eye movements during a visual exploration task?\n* Does cTBS change brain activity patterns linked to attention networks, as measured by EEG?\n\nResearchers will compare different conditions, cerebellar cTBS, cerebral cTBS and sham cTBS to see which approach best improves visuospatial attention. Sham cTBS looks and feels identical to real stimulation but does not deliver effective magnetic pulses.\n\nParticipants, who are already admitted to the neurology and neurorehabilitation ward, will attend four study visits over approximately two weeks, each lasting about one hour. They receive active or sham cTBS at three stimulation sessions, each separated by at least 48 hours. They also have their eye movements recorded using a camera-based eye-tracking system before and after each session and have their brain activity recorded using EEG, a method that measures electrical activity through small electrodes on the scalp. Participation is voluntary. Participants may withdraw at any time without any impact on their regular medical care. The study is conducted at the Neurocenter of Luzerner Kantonsspital, Switzerland, and is funded by the Swiss National Science Foundation (SNF).",[26,27,28],"Hemispatial Neglect","Visual Neglect","Stroke",[30,28,31,32],"Neglect","cTMS","Cerebellum","NOT_YET_RECRUITING","2026-05-06",{"date":36,"type":37},"2026-05-12","ACTUAL",{"date":39,"type":20},"2026-05-05",{"date":41,"type":20},"2030-04",{"name":43,"class":44},"Luzerner Kantonsspital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100629546","optimization-and-validation-of-electric-acoustic-stimulation-eas-mapping-as-a-function-of-residual-hearing-after-ci-implantation-100629546","NCT07476079","Optimization and Validation of Electric Acoustic Stimulation (EAS) Mapping as a Function of Residual Hearing After CI-Implantation","Inclusion Criteria:\n\n1. Patients aged between 18-85 years.\n2. Cochlear Implant (CI) candidates with measurable post-operative low-frequency residual hearing (125Hz \\\u003C65dB, 250Hz \\\u003C65dB, 500Hz \\\u003C65dB).\n3. Only patients with MED-EL EAS.\n4. Written informed consent must be obtained prior to study start.\n\nExclusion Criteria:\n\n1. Patients with cognitive impairments who, as a result, lack the capacity to make decisions.\n2. Uncooperative patients regarding pure tone audiometry thresholds measurements.\n3. Morbus Menière or intracochlear\u002F vestibular schwannoma","85 Years",{"count":54,"type":20},12,[23],"The aim of this clinical study is to investigate how the fitting of an EAS (electrical acoustic stimulation) based on electrocochleography (ECochG) thresholds compares to fitting based on pure tone audiogram thresholds in terms of speech intelligibility in quiet and noise. The personal feedback from the study participants regarding the question of better fitting and the resulting sound quality should also be included in the analysis.",[58],"Fitting Methods by EAS Patients",[60,61,62,63,64],"Cochlear Implant patients","Residual hearing in the low frequency range","EAS","fitting methods","electrocochleography","2026-04-23",{"date":67,"type":37},"2026-04-24",{"date":69,"type":20},"2026-05-01",{"date":71,"type":20},"2027-11-01",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":45},"100633968","chrononutrition-in-preterm-infants-a-randomised-controlled-trial-of-time-matched-breast-milk-feeding-and-its-effects-on-sleep-and-circadian-development-100633968","NCT07533578","Chrononutrition in Preterm Infants: a Randomised Controlled Trial of Time-matched Breast Milk Feeding and Its Effects on Sleep and Circadian Development","Inclusion Criteria:\n\n* Preterm infants born between 32+0 and 36+6 weeks' gestation\n* Age ≤ 1 month at enrolment\n* Infants routinely receiving expressed breast milk (fully or partially breastfed)\n* Written informed consent obtained from parent(s) or legal representative(s)\n* Ability of caregivers to comply with study procedures including milk labelling and feeding according to study allocation\n\nExclusion Criteria:\n\n* Prenatal exposure to illicit drugs (e.g. cannabis, cocaine, heroin, opiates) or significant alcohol exposure\n* Major congenital malformations or congenital infections\n* Significant underlying disease (excluding transient neonatal conditions such as feeding difficulties, hyperbilirubinaemia, hypoglycaemia, anaemia, respiratory distress syndrome, or apnoea-bradycardia syndrome)",true,"0 Days","1 Month",{"count":83,"type":20},200,[23],"This study investigates whether the timing of feeding expressed breast milk influences infant sleep and circadian (day-night) development in preterm infants.\n\nIn early life, infants produce very little of the hormone melatonin, which plays a key role in regulating sleep and circadian rhythms. Breast milk naturally contains melatonin, and its levels vary across the day, with higher concentrations at night. This variation may provide important biological signals that help infants develop healthy sleep-wake patterns.\n\nHowever, expressed breast milk is often fed without considering the time it was expressed. This may disrupt the transfer of circadian signals from mother to infant.\n\nThe aim of this randomised controlled trial is to determine whether feeding expressed breast milk according to the time of expression (e.g. giving night-time milk at night) improves sleep consolidation and circadian development compared with usual feeding practices.\n\nA total of 200 preterm infants born between 32+0 and 36+6 weeks' gestation who are receiving expressed breast milk will be enrolled and randomly assigned to one of two groups:\n\nIntervention group: preterm infants receive expressed breast milk matched to the time of day it was expressed (day, evening or night)\n\nControl group: preterm infants receive expressed breast milk without regard to timing (usual practice)\n\nThe main outcome is sleep consolidation at 6 months of age, measured objectively using actigraphy (a small wearable device that records sleep and activity). Additional outcomes include sleep patterns over time, circadian development, melatonin exposure, gut microbiota composition, and clinical outcomes such as infections and neurodevelopment.\n\nThe intervention does not involve any medication and uses the infant's usual nutrition. Risks are minimal and mainly relate to the additional effort required for milk labelling and timing.\n\nThis study will provide evidence on whether a simple, low-risk change in feeding practice can support infant sleep and early-life circadian development, with potential benefits for child health and family well-being.",[87,88,89],"Infant Sleep Problems","Circadian Rhythm","Neurodevelopment",[91,92,88,93,94,95,96,97,98,99,100,101,102],"Chrononutrition","Breast Milk","Circadian Development","Infant Sleep","Sleep Consolidation","Melatonin","Infant Microbiome","Gut Microbiota","Chronobiology","Sleep-Wake Cycle","Actigraphy","Randomized Controlled Trial","2026-04-10",{"date":105,"type":37},"2026-04-16",{"date":107,"type":20},"2026-10-01",{"date":109,"type":20},"2031-12-30",{"name":43,"class":44},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100612678","hypnosis-and-attention-in-patients-with-a-neurological-disease-stroke-traumatic-brain-injury-and-multiple-sclerosis-100612678","NCT07256704","Hypnosis and Attention in Patients With a Neurological Disease (Stroke, Traumatic Brain Injury and Multiple Sclerosis)","Hypnosis and Attention in Patients With a Neurological Disease","HYPNOVA","Inclusion Criteria:\n\nICD-10 Diagnosis of stroke, TBI or MS Admitted to the inpatient and\u002For outpatient in the Clinic for Neurology and Neurorehabilitation Age 18 years old or older Understanding the German language Written informed consent\n\nExclusion Criteria:\n\nPsychiatric disease\n\nExclusion criteria for the EEG:\n\nScalp or skin conditions that interfere with EEG electrode placement (e.g. open wounds, infections, severe psoriasis) Implanted medical or neurostimulation devices that interfere with EEG electrode placement (e.g. deep brain stimulators, cochlear implants)",{"count":120,"type":20},48,[23],"This feasibility study investigates the potential of hypnosis as a complementary therapy to improve attentional deficits and fatigue in patients with neurological diseases such as stroke, traumatic brain injury (TBI), and multiple sclerosis (MS). These patients often experience reduced spontaneous visual exploration and impaired functional independence despite current rehabilitation methods. By integrating hypnosis with standard care, and using EEG to monitor brain activity during hypnosis and sham-hypnosis sessions, this trial aims to evaluate the practicality, acceptability, and preliminary efficacy of hypnosis in enhancing attention and reducing fatigue.",[28,124,125],"Traumatic Brain Injury","Multiple Sclerosis",[127,128,129,130],"Hypnosis","Attention deficit","Neurorehabilitation","Electroencephalography (EEG)","RECRUITING","2025-11-20",{"date":134,"type":37},"2025-12-01",{"date":136,"type":37},"2025-11-18",{"date":138,"type":20},"2029-07-31",{"name":43,"class":44},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":159,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":45},"100597180","digital-aftercare-for-wrist-and-clavicle-fractures-100597180","NCT07055139","Digital Aftercare for Wrist and Clavicle Fractures","Comparison of Digital Versus Traditional Aftercare for Uncomplicated Distal Radius and Clavicle Fractures","DA-DRAC","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Surgically treated, uncomplicated distal radius or clavicle fracture\n* Use of a smartphone (iOS or Android)\n* Ability to understand German and complete study-related questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Polytrauma or additional injuries to the same upper extremity\n* No access to or inability to use a smartphone\n* Cognitive, psychiatric, or language barriers impairing participation\n* Pregnancy\n* Inability or unwillingness to comply with the study protocol","65 Years",{"count":150,"type":20},84,[23],"This prospective, two-arm, open-label clinical trial compares digital aftercare with traditional follow-up in adult patients after surgical treatment of uncomplicated distal radius or clavicle fractures. The primary objective is to assess functional recovery at three months, using the Patient-Rated Wrist Evaluation (PRWE) for wrist fractures and the QuickDASH for clavicle fractures. Secondary outcomes include range of motion, patient satisfaction, quality of life, complication rates, healthcare costs, and work disability. In the digital aftercare group, program adherence and user experience will also be evaluated through app usage data and a structured questionnaire. The study aims to determine whether digital aftercare is a clinically and economically equivalent alternative to standard in-person care.",[154,155,156,157,158],"Distal Radius Fracture","Clavicle Fracture","Postoperative Care","Patient-Reported Outcome Measures (PROMs)","Upper Extremity Fractures",[160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,156],"distal radius fracture","clavicle fracture","digital aftercare","app-based aftercare","App-Based Rehabilitation","Wrist Fracture","Fracture Recovery","Functional Outcome","QuickDASH","PRWE","eHealth","Patient Satisfaction","Quality of Life","EQ-5D","Complication Rate","2025-06-27",{"date":177,"type":37},"2025-07-08",{"date":179,"type":20},"2025-09-01",{"date":181,"type":20},"2027-03-31",{"name":43,"class":44},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":45},"100582932","swiss-spinal-tumor-registry-swiss-str-100582932","NCT06869746","Swiss Spinal Tumor Registry (Swiss-STR)","SSTR","Inclusion Criteria:\n\n* Diagnosis of primary spinal tumor\n* Diagnosis of secondary (metastatic) spinal tumor\n* Indication for surgical treatment is present\n* Patient age: =\u002F\\>18 years\n\nExclusion criteria:\n\n* Withdrawal of consent\n* Withdrawal from initially planned surgical procedure\n* Patient age: \\\u003C18 years",{"count":191,"type":20},250,"2 Years","OBSERVATIONAL","The Swiss Spinal Tumor Registry is a prospective REDCap-based registry, collecting data of surgically treated patients with primary and metastatic tumors of the spine.",[196,197],"Spinal Tumors","Surgical Treatment",[199,200],"Spinal Tumor","Spinal Metastasis","2025-03-14",{"date":203,"type":37},"2025-03-19",{"date":205,"type":37},"2023-01-01",{"date":207,"type":20},"2032-12-31",{"name":43,"class":44},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":218,"studyType":193,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":45},"100521900","complex-registry---a-prospective-cohort-study-to-describe-the-management-and-outcomes-of-patients-presenting-with-complex-and-calcified-coronary-artery-disease-100521900","NCT06075602","COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease","COMPLEX","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals presenting with chronic, complex and\u002For calcified CAD and requiring PCI or CABG\n* Complex coronary artery disease \u002F lesions must include at least one of the following attributes:\n* Long and\u002F or heavily calcified coronary lesions\n* In-stent restenosis\n* Chronic total occlusions (CTO)\n* Left main lesions\n* Bifurcation lesions\n* Bypass graft lesions\n* Small vessel disease \u002F coronary microvascular dysfunction (e.g. not amenable to PCI)\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the patient.\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* Patients with no complex and calcified CAD",{"count":217,"type":20},5000,"10 Years","The purpose of the COMPLEX Registry is to prospectively and retrospectively collect baseline, clinical and procedural data of patients who have undergone PCI or CABG for complex and\u002F or calcified chronic CAD, irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. The outcomes will be compared in different clinical subgroups (e.g. PCI vs. CABG). The impact of current PCI techniques\u002F devices, but also CABG strategies in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[221,222,223,224,225,226,227,228,229,230],"Coronary Disease","Coronary Artery Disease","Coronary Restenosis","Coronary Arteriosclerosis","Coronary Artery Calcification","Stable Chronic Angina","Angina Pectoris","Angina, Stable","Angina, Unstable","Stent Thrombosis","2024-10-27",{"date":233,"type":37},"2024-10-29",{"date":235,"type":37},"2021-11-01",{"date":237,"type":20},"2031-12-31",{"name":43,"class":44},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":218,"studyType":193,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":45},"100438392","siroop-registry---a-prospective-registry-study-to-evaluate-the-outcomes-of-coronary-artery-disease-patients-treated-with-sirolimus-or-paclitaxel-eluting-balloon-catheters-100438392","NCT04988685","SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters","SIROOP","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Patients with significant acute or chronic coronary de-novo lesions or ISR lesions requiring treatment using PCI\n* Treatment with at least one DCB (device choice at the operator's discretion) In case of a patient with lesions treated at different procedural time, lesions will be separately collected and documented\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* pregnancy and lactation\n* Indication for surgical revascularization",{"count":247,"type":20},2000,"The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[221,222,223,224,225,226,227,228,229,230],{"date":233,"type":37},{"date":252,"type":37},"2021-06-01",{"date":237,"type":20},{"name":43,"class":44},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":79,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":4},"100560549","comparison-of-gastric-insufflation-with-the-classic-igel-laryngeal-mask-and-the-new-igelplus-laryngeal-mask-using-gastric-ultrasound-100560549","NCT06578598","Comparison of Gastric Insufflation With the Classic Igel Laryngeal Mask and the New Igelplus Laryngeal Mask Using Gastric Ultrasound","Comparison of Gastric Air Insufflation and Ventilation Between Two Laryngeals Masks (LMA): Igel and Igelplus","Inclusion Criteria:\n\n* Patients with ASA classification 1-2\n* Undergoing elective surgery\n* Body Mass Index (BMI) \\\u003C 35\n* No contraindications for the laryngeal mask\n\nExclusion Criteria:\n\n* Presence of contraindications for the laryngeal mask\n* Urgent or non-elective surgeries",{"count":83,"type":20},[23],"This study aims to compare the effectiveness and safety of two types of laryngeal masks- iGel and iGel Plus, used during elective surgeries. The focus is on evaluating differences in gastric insufflation and ventilation parameters between these two devices. Participants will be patients classified as ASA 1-2 with a BMI of less than 35, undergoing elective procedures.\n\nThe study is designed as a prospective, randomized, controlled trial with 200 subjects divided evenly between the two laryngeal mask groups. Key outcomes include gastric cross-sectional area (CSA) measurements before and after surgery, ventilation metrics such as leakage pressure and PEEP, and the incidence of postoperative complications like nausea and respiratory issues.",[266,267],"Surgery","Anesthesia","2024-08-27",{"date":270,"type":37},"2024-08-29",{"date":272,"type":20},"2024-10-01",{"date":134,"type":20},{"name":43,"class":44},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":45},"100465849","the-value-of-ivl-compared-to-opn-non-compliant-balloons-for-treatment-of-refractory-coronary-lesions-victory-trial-100465849","NCT05346068","The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial","The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial - A Randomized, Multicenter, Non-inferiority Comparison of Shockwave Intravascular Lithotripsy (IVL) and the OPN Non-compliant Balloon for Treatment of Calcified and Refractory Coronary Lesions","VICTORY","Clinical inclusion criteria:\n\n* Age ≥18 years and consentable;\n* Acute or chronic coronary artery disease with ischemia related symptoms (e.g. angina) and\u002For evidence of myocardial ischemia (e.g. FFR\u002F iFR, CMR, SPECT or PET-CT);\n* Angiographically-proven coronary artery disease;\n* Lesions in non-target vessels requiring PCI may be treated either\n\n  * prior to the study procedure if the procedure was unsuccessful or complicated; or\n  * in the same session if feasible and safe for the patient, otherwise a staged PCI procedure for non-target vessels may be considered;\n* Informed Consent signed by the subject.\n\nAngiographic inclusion criteria:\n\n* Single de novo target lesion stenosis of protected LMCA, or LAD, RCA or LCX (or of their branches) with\\*:\n\n  * Stenosis of ≥70%;\n  * Stenosis ≥50% and \\\u003C70% (visually assessed) with evidence of ischemia via positive stress test, or fractional flow reserve value ≤0.80, or iFR \\\u003C0.90 or IVUS minimum lumen area ≤4.0 mm²;\n* The target vessel reference diameter must be ≥2.5 mm \\& ≤4.5mm;\n* AND AT LEAST ONE OF THE FOLLOWING CRITERIA:\n\n  * Evidence of calcification at the lesion site by angiography (Grade 3), with fluoroscopic radio-opacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion,\n  * AND\u002F OR by OCT, with presence of ≥270° calcium;\n  * AND\u002F OR Prior attempt at PCI with inability to expand a balloon in target lesion.\n\nAnnotation: Only one lesion and vessel per randomized patient may be treated according to protocol and considered for the purpose of this study. The lesion considered for the study should represent the most calcified one.\n\nThe presence of any one of the following exclusion criteria will lead to the exclusion of the subject:\n\nExclusion criteria:\n\n* Patient experienced an acute STEMI or cardiogenic shock related to an acute MI within 2 days prior to index procedure;\n* Any comorbidity or condition which may reduce compliance with this protocol, including follow-up calls\u002F visits (e.g. advanced dementia);\n* Any medical, geographic, and\u002For social factor making study participation impractical or precluding required follow-up.\n* Patient is pregnant or nursing (a negative pregnancy test is required for women of child-bearing potential within 7 days prior to enrollment);\n* Unable to take a P2Y12 inhibitor (i.e. clopidogrel, prasugrel, or ticagrelor) for at least 6 months;\n* Patient has an allergy to imaging contrast media which cannot be adequately pre-medicated;\n* Renal failure with an eGFR \\\u003C30ml\u002Fmin1.73m2;\n* History of a stroke or transient ischemic attack (TIA) within 7 days, or any prior intracranial hemorrhage;\n* Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months;\n* Untreated pre-procedural hemoglobin \\\u003C10g\u002FdL or intention to refuse blood transfusions if one should become necessary;\n* Patient has an allergy or intolerance to cobalt-chromium and\u002F or everolimus.\n* Life expectancy of less than 1 year.\n\nAngiographic exclusion criteria:\n\n* Anatomy where the device or OCT catheter are unlikely to be delivered due to tortuosity or other characteristics;\n* Target lesion is in a coronary artery bypass graft;\n* Target lesion is an in-stent restenosis (ISR);\n* Flow limiting target vessel thrombus (evident on angiography or OCT);\n* Definite or possible thrombus (by angiography or intravascular imaging) in the target vessel;\n* Evidence of aneurysm in target vessel within 10 mm of the target lesion.\n\nOf note, only qualified physicians who are investigators or a sub-investigators for the trial will assess each individual´s eligibility criteria and take the final decision to include the subject in the trial (ICH GCP 4.3.1). This decision will be documented prior to the subject receiving the first intervention.",{"count":284,"type":20},280,[23],"Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation has become the dominant treatment strategy for patients with acute and chronic coronary artery disease (CAD) requiring revascularization. Nonetheless, PCI with stent implantation has some limitations and especially patients with severely calcified coronary lesions (approximately 10-20% of all patients with CAD) have an elevated risk for adverse outcomes, including target lesion failure (TLF) and stent thrombosis (ST).\n\nSeveral dedicated PCI devices have been developed for treatment of severely calcified lesions. Whereas especially two of them have shown promising results in smaller, prospective studies. First, the super high-pressure NC PCI balloon (OPN™ NC, SIS Medical AG, Frauenfeld, Switzerland) has been shown to represent an effective and safe device for lesion preparation. Second, the lately introduced Shockwave intravascular lithotripsy (IVL)™ balloon catheter (Shockwave Medical, Santa Clara, CA, USA) appears to be a safe and efficient alternative device for treatment of calcified coronary lesions. However, it remains unknown, if the OPN™ NC balloon is non-inferior to to IVL regarding lesion preparation and completeness of stent expansion in severely calcified lesions.",[221,222,288,289,225],"Calcific Coronary Arteriosclerosis","Stent Restenosis","2024-06-16",{"date":292,"type":37},"2024-06-18",{"date":294,"type":37},"2022-11-22",{"date":296,"type":20},"2028-05-30",{"name":43,"class":44},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":45},"100521834","subsartorial-nerve-block-and-femoral-nerve-block-in-total-knee-arthroplasty-100521834","NCT06074744","Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty","Subsartorial Saphenous Nerve Block (SSNB) Versus Femoral Nerve Block (FNB) in Primary Total Knee Arthroplasty (TKA) Combined With Infiltration Between Popliteal Artery and Capsule of the Knee (IPACK) - Where Are the Benefits?","Inclusion criteria:\n\n* age \\> 18yrs\n* primary TKA\n* BMI 35kg\u002Fm2 or less\n* able to give informed consent as documented by signature\n* clinical history without any contraindications for the planned intervention\n\nExclusion criteria:\n\n* age \\\u003C 18 years\n* revision-TKA\n* BMI \\>35kg\u002Fm2\n* absent contact information\n* inability or contraindications to undergo the investigated intervention (TKA, FNB, SSNB), - clinically significant concomitant diseases\n* pregnancy\n* inability to follow the procedures and follow-up procedures of the study (e.g. due to language problems, psychological disorders, dementia, living abroad, etc.\n* withdrawal from the study",{"count":306,"type":20},144,[23],"The goal of this clinical trial is to compare two different types of nerve blocks in patients undergoing surgery for primary Total Knee Arthroplasty. The main question aim to answer is:\n\n\\- is there a benefit in functional muscle power output of the leg?\n\nParticipants will be randomized into either the intervention group or the control group and:\n\n* receive Subsartorial Saphenous Nerve Block (SSNB) + IPACK in intervention group (group 1)\n* receive Femoral Nerve Block (FNB) + IPACK in control group (group 2)\n\nResearchers will compare the 2 groups to see if there are differences in :\n\n* functional muscle power output of the leg?\n* muscle function, mobility, clinical and radiological results, ROM, pain control (NRS), opioid consumption, length of hospital stay, patient satisfaction, mobility, reduction of costs?",[310,311],"Joint Diseases","Joint Pain",[313,314,315],"Subsartorial Saphenous Nerve Block (SSNB)","Femoral Nerve Block (FNB)","Total Knee Arthroplasty (TKA)","2024-03-07",{"date":318,"type":37},"2024-03-12",{"date":320,"type":37},"2023-11-30",{"date":322,"type":20},"2026-12",{"name":43,"class":44},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":45},"100438391","optimiser-registry---a-prospective-cohort-study-to-describe-the-optimal-management-and-outcomes-of-patients-presenting-with-acute-myocardial-infarction-100438391","NCT04988672","OPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction","OPTIMISER","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals who are newly diagnosed with AMI or have been diagnosed with AMI (STEMI or NSTEMI) within the last 5 years (since 2016).\n* Subjects must be willing to sign a patient informed consent (PIC) OR a patient ́s relative\u002F proxy are willing to provide PIC or patients have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient unwilling or unable to provide informed consent\n* Patients with no ACS\u002FAMI (e.g. Takotsubo cardiomyopathy, acute heart failure not related to AMI)",{"count":332,"type":20},4000,"The purpose of the OPTIMISER Registry is to prospectively and retrospectively collect baseline, clinical and procedural data in patients who present with AMI and are treated with PCI as well as prospectively collect the clinical outcome data. Outcomes will be compared in different clinical subgroups. The impact of PCI in AMI in general as well as cardiovascular outcomes after AMI will be assessed.",[335,336,337,338],"Myocardial Infarction","Myocardial Ischemia","STEMI","NSTEMI","2023-10-04",{"date":341,"type":37},"2023-10-06",{"date":343,"type":37},"2021-01-01",{"date":345,"type":20},"2030-12-31",{"name":43,"class":44},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":79,"sex":16,"minAge":17,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":45},"100520909","new-interactive-sensor-home-based-hand-training-to-improve-dexterity-100520909","NCT06062693","New Interactive Sensor-home-based Hand Training to Improve Dexterity","Inclusion Criteria:\n\n* Patients with confirmed PD, according to UK Brain bank Criteria (Hughes et al., 1992) or\n* MS patients with relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS) or primary progressive MS (PPMS) according to the revised McDonald's criteria or\n* subacute stroke\n* written and signed informed consent\n* self-reported hand function problems\n\nor\n\n* healthy subject\n* written and signed informed consent\n* no self-reported hand function problems\n\nExclusion Criteria:\n\n* MoCA \\\u003C21\u002F30\n* psychiatric disease\n* participation on other interventional trials\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.","99 Years",{"count":355,"type":20},160,[23],"Primary objective of this study is to explore the impact of a 3-week upper limb hand function training in patients with PD, MS or stroke. The benefits on hand function of this training program will be evaluated. The hypothesize is that the 3-week upper limb hand function training improves finger dexterity.",[28,125,359],"Parkinson Disease",[361,362],"dexterity","training","2023-09-28",{"date":365,"type":37},"2023-10-02",{"date":367,"type":37},"2023-06-01",{"date":369,"type":20},"2027-08-30",{"name":43,"class":44},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":387,"leadSponsor":389,"locationsCount":45},"100485093","role-of-intrapulmonary-lymph-nodes-in-patients-with-nsclc-and-visceral-pleural-invasion-100485093","NCT05596578","Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion","Inclusion Criteria:\n\n* Anatomical resection for NSCLC \\\u003C3 cm (lobectomy, bilobectomy, segmentectomy)\n* Samples from the intrapulmonary stations 12, 13, and 14 lymph nodes\n* Resection of lymphnodes station 10 and 11 during hilar separation.\n* R0 resection\n\nExclusion Criteria:\n\n* Prior or synchronous lung cancer\n* pN2\n* Pneumonectomy\n* R1\u002FR2 resection\n* M1\n* Neoadjuvant treatment",{"count":378,"type":20},958,"Background: Lung cancer is the leading cause of cancer related death worldwide. More than 80% of all lung tumors are Non-Small Cell Lung Cancers (NSCLC). Lymph node staging has a prognostic value and is crucial to establish the optimal treatment strategy in individual patients. It remains unknown whether dissecting the intrapulmonary lymph nodes (stations 13 and 14) is necessary for accurate staging and prognostication. Although suggested by several guidelines, these peripheral lymph nodes are not routinely examined in clinical routine for several reasons. Moreover, the prognostic significance of the visceral pleural invasion is controversial. Some studies showed a negative impact on OS and DFS in patients with histologic proved visceral pleura invasion.\n\nThe mechanism to explain this negative effect is not fully understood. Given that the visceral pleura is very rich in lymphatic vessels, with an intercommunicating \"network\" arranged over the lung surface and penetrating into the lung parenchyma to join the bronchial lymph vessels with drainage to the various hilar nodes, we assume that the worse OS and DFS observed in these patients could be explained with the presence of metastatic lymph nodes (Station 13-14) that are not routinely examined. Methods: This is a prospective, multicenter study based on ad-hoc created prospectively database. The incidence of N1 lymph node metastasis overall and the incidence of metastasis to the different lymph node stations (Hilar 10\u002F11, Lobar 12, Sublobar 13\u002F14) will be calculated by dividing the number of the respective events by the patient years separately. To investigate the association between visceral pleural invasion and the presence of metastatic lymph nodes univariate and multivariate logistic regression models will be fitted to the data.\n\nDiscussion: The primary outcome is to investigate the incidence of N1 metastases (especially stations 12,13,14) and his relationship with visceral pleural invasion. The secondary outcomes is to evaluate the impact of N1 metastases and\u002For visceral pleural invasion on long-term outcomes (OS and DFS) along with incidence and pattern of recurrence. DFS is defined as the time of surgical intervention to tumor recurrence or death, and OS is defined as the time of surgical intervention to death",[381,382],"Lung Cancer","Lymph Node Metastasis","2023-01-05",{"date":385,"type":37},"2023-01-09",{"date":205,"type":37},{"date":388,"type":20},"2029-12-31",{"name":43,"class":44},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":396,"targetDuration":218,"studyType":193,"phases":4,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":45},"100325748","luks-leads-registry-on-long-term-performance-of-icd-leads-100325748","NCT03521050","LUKS-Leads Registry on Long-term Performance of ICD Leads","Inclusion Criteria:\n\n* all patients being implanted with a Defibrillator lead from 2006 onwards\n\nExclusion Criteria:\n\n* documented refusal of data collection for scientific purposes",{"count":397,"type":20},1000,"All patients having an implantable cardiac defibrillator (ICD) implanted and having follow-up at the Cantonal Hospital Lucerne (LUKS), the investigator center, are included in this retrospective ICD lead registry from 2006 onwards. Data is collected prospectively from december 2016 onwards. After certain ICD-leads tended to fail early the investigators aimed for a registry monitoring our patient population with defibrillator leads and evaluating their long-term performance.",[400,401],"Defibrillators","Electrical Shock","2020-09-02",{"date":404,"type":37},"2020-09-04",{"date":406,"type":37},"2016-12",{"date":322,"type":20},{"name":43,"class":44},""]